Talk:PD-1 and PD-L1 inhibitors
Latest comment: 5 years ago by Rod57 in topic Adverse effects should mention hyperprogressive disease
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
Should give more weight to PD-1 inhibitors ? edit
More of them have been approved eg by the FDA, yet this article seems to ignore their existence. - Rod57 (talk) 21:31, 12 June 2016 (UTC)
May be able to use on mCRC (eg with MEK-inhibitors) edit
Anti-PD-L1 immunotherapy responsive in microsatellite-stable mCRC comb with MEK inhibition. une 2016 says it can be helpful to use them with MEK-inhibitors for mCRC types that have previously been hard to treat with immunotherapies. - Rod57 (talk) 21:22, 2 July 2016 (UTC)
Adverse effects should mention hyperprogressive disease edit
Adverse effects section should mention hyperprogressive disease' per Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy - Rod57 (talk) 17:00, 21 September 2018 (UTC)